Kenya Cancer Immunotherapy Market Analysis

Kenya Cancer Immunotherapy Market Analysis


$ 3999

Kenya's cancer immunotherapy market is expected to witness growth from $79 Mn in 2022 to $148 Mn in 2030 with a CAGR of 8.2% for the forecasted year 2022-30. The rising prevalence of cancer in Kenya and technological advancements in the treatment of cancer in Kenya are the main drivers of the market. The Kenya cancer immunotherapy market is segmented by type, application, and end user. Sunpar Pharmaceuticals, Wessex Pharmaceuticals, and Celgene are the major players in the Kenya cancer immunotherapy market.

ID: IN10KEPH032 CATEGORY: Pharmaceuticals GEOGRAPHY: Kenya AUTHOR: Dr. Parul Choudhary

Buy Now

Kenya Cancer Immunotherapy Market Executive Analysis

Kenya's cancer immunotherapy market is expected to witness growth from $79 Mn in 2022 to $148 Mn in 2030 with a CAGR of 8.2% for the forecasted year 2022-30. For health care services, the government has budgeted $1.08 Bn in the 2022–23 fiscal year. The ability of healthcare professionals to give high-quality services supported by well-stocked and equipped healthcare facilities is dependent on their availability, accessibility, and capacity. $0.46 Bn of the $1.08 Bn budgeted for health care will go toward actions and programs aimed at achieving universal coverage. The cost of COVID-19 vaccines and related expenses has been budgeted at $52 Mn, with $29 Mn set aside for free maternity healthcare. $0.12 Bn has been earmarked to reduce the number of instances of HIV/AIDS, malaria, and tuberculosis in the nation, with $38 Mn set aside to improve vaccinations and immunization programs.

After cardiovascular disease and infectious disorders, cancer is the third leading cause of morbidity in Kenya (7% of deaths annually). In Kenya, there are an estimated 39,000 new instances of cancer each year, and more than 27,000 people die from it. 60% of Kenyans who have cancer are under the age of 70.

The development of cancer immunotherapy is still in its infancy in Kenya. However, initiatives have been made to improve the nation's access to these therapies. Currently, checkpoint inhibitors and CAR-T cell therapy are the most popular kinds of cancer immunotherapy used in Kenya. Drugs called checkpoint inhibitors stop the proteins that cancer cells employ to get around the immune system. In Kenya, the use of these medications has been authorized for the treatment of melanoma, non-small cell lung cancer, and bladder cancer. Immunotherapy known as CAR-T cell treatment includes genetically altering a patient's own immune cells to target cancer cells more effectively. Currently, Kenya has access to this medication for the treatment of specific blood malignancies like leukaemia and lymphoma.

Kenya Cancer Immunotherapy Market Analysis

Market Dynamics

Market Growth Drivers

Kenya's rising cancer prevalence has increased the demand for efficient treatment options. The Kenya Cancer Statistics 2021 study estimates that there were 47,887 new cancer cases in Kenya in 2020. A tailored therapy called immunotherapy makes use of the patient's own immune system to combat cancer. Demand for these treatments is anticipated to rise as patients and medical professionals become more aware of the potential advantages of immunotherapy. Technology advancements, including the creation of novel biomarkers and tailored medicine, are facilitating the creation of more potent cancer immunotherapies. The Kenya cancer immunotherapy market is anticipated to expand as a result of these developments.

Market Restraints

Oncologists and other experts are in low supply, and Kenya's healthcare system is still under development. Patients may find it challenging to obtain cancer immunotherapy and other cutting-edge treatments as a result. Cancer treatment has a high price tag and may be out of reach for certain patients. This is particularly true in low- and middle-income nations like Kenya, where access to cancer treatment is severely hampered by the high expense of care. Kenya's lengthy and intricate licensing procedures for new cancer immunotherapies have the potential to stall their commercialization hence limiting the growth of the Kenya cancer immunotherapy market.

Competitive Landscape

Key Players

  • Regal Pharmaceuticals (KEN)
  • Cosmos Pharmaceuticals (KEN)
  • Mac's Pharmaceuticals (KEN)
  • Sunpar Pharmaceuticals (KEN)
  • Wessex Pharmaceuticals (KEN)
  • Celgene
  • Amgen
  • Merck
  • Janssen
  • Seattle Genetics
  • Printegra
  • Gristone Oncology
  • Pfizer

Healthcare Policies and Regulatory Landscape

For formal sector employees, health insurance is required through the National Hospital Insurance Fund (NHIF), whereas it is optional for self-employed individuals and those engaged in the unorganized sector. Inpatient and outpatient therapies, including cancer treatment, are covered by NHIF, while some procedures and drugs may have a lower level of coverage. Additionally, the National Cancer Control Strategy (NCCS), which aims to enhance palliative care, cancer diagnosis, treatment, and prevention, was formed by the Kenyan government. The NCCS has clauses that cover financial security and compensation for cancer treatments, including immunotherapy.

1. Executive Summary
1.1 Disease Overview
1.2 Global Scenario
1.3 Country Overview
1.4 Healthcare Scenario in Country
1.5 Patient Journey
1.6 Health Insurance Coverage in Country
1.7 Active Pharmaceutical Ingredient (API)
1.8 Recent Developments in the Country

2. Market Size and Forecasting
2.1 Epidemiology of Disease
2.2 Market Size (With Excel & Methodology)
2.3 Market Segmentation (Check all Segments in Segmentation Section)

3. Market Dynamics
3.1 Market Drivers
3.2 Market Restraints

4. Competitive Landscape
4.1 Major Market Share

4.2 Key Company Profile (Check all Companies in the Summary Section)

4.2.1 Company
4.2.1.1 Overview
4.2.1.2 Product Applications and Services
4.2.1.3 Recent Developments
4.2.1.4 Partnerships Ecosystem
4.2.1.5 Financials (Based on Availability)

5. Reimbursement Scenario
5.1 Reimbursement Regulation
5.2 Reimbursement Process for Diagnosis
5.3 Reimbursement Process for Treatment

6. Methodology and Scope

Cancer Immunotherapy Segmentation

By Type (Revenue, USD Billion):

  • Monoclonal Antibodies
  • Cancer Vaccines
  • Checkpoint Inhibitors
  • Immunomodulators
  • PD-1/PD-L1
  • CTLA-4

By Application (Revenue, USD Billion):

  • Lung Cancer
  • Breast Cancer
  • Head and Neck Cancer
  • Prostate Cancer
  • Colorectal Cancer
  • Melanoma
  • Others

By End User (Revenue, USD Billion):

  • Hospitals
  • Clinics
  • Ambulatory Surgical Centers (ASCs)
  • Cancer Research Centers

Methodology for Database Creation

Our database offers a comprehensive list of healthcare centers, meticulously curated to provide detailed information on a wide range of specialties and services. It includes top-tier hospitals, clinics, and diagnostic facilities across 30 countries and 24 specialties, ensuring users can find the healthcare services they need.​

Additionally, we provide a comprehensive list of Key Opinion Leaders (KOLs) based on your requirements. Our curated list captures various crucial aspects of the KOLs, offering more than just general information. Whether you're looking to boost brand awareness, drive engagement, or launch a new product, our extensive list of KOLs ensures you have the right experts by your side. Covering 30 countries and 36 specialties, our database guarantees access to the best KOLs in the healthcare industry, supporting strategic decisions and enhancing your initiatives.

How Do We Get It?

Our database is created and maintained through a combination of secondary and primary research methodologies.

1. Secondary Research

With many years of experience in the healthcare field, we have our own rich proprietary data from various past projects. This historical data serves as the foundation for our database. Our continuous process of gathering data involves:

  • Analyzing historical proprietary data collected from multiple projects.
  • Regularly updating our existing data sets with new findings and trends.
  • Ensuring data consistency and accuracy through rigorous validation processes.

With extensive experience in the field, we have developed a proprietary GenAI-based technology that is uniquely tailored to our organization. This advanced technology enables us to scan a wide array of relevant information sources across the internet. Our data-gathering process includes:

  • Searching through academic conferences, published research, citations, and social media platforms
  • Collecting and compiling diverse data to build a comprehensive and detailed database
  • Continuously updating our database with new information to ensure its relevance and accuracy

2. Primary Research

To complement and validate our secondary data, we engage in primary research through local tie-ups and partnerships. This process involves:

  • Collaborating with local healthcare providers, hospitals, and clinics to gather real-time data.
  • Conducting surveys, interviews, and field studies to collect fresh data directly from the source.
  • Continuously refreshing our database to ensure that the information remains current and reliable.
  • Validating secondary data through cross-referencing with primary data to ensure accuracy and relevance.

Combining Secondary and Primary Research

By integrating both secondary and primary research methodologies, we ensure that our database is comprehensive, accurate, and up-to-date. The combined process involves:

  • Merging historical data from secondary research with real-time data from primary research.
  • Conducting thorough data validation and cleansing to remove inconsistencies and errors.
  • Organizing data into a structured format that is easily accessible and usable for various applications.
  • Continuously monitoring and updating the database to reflect the latest developments and trends in the healthcare field.

Through this meticulous process, we create a final database tailored to each region and domain within the healthcare industry. This approach ensures that our clients receive reliable and relevant data, empowering them to make informed decisions and drive innovation in their respective fields.

To request a free sample copy of this report, please complete the form below.


We value your inquiry and offer free customization with every report to fulfil your exact research needs.

Sunpar Pharmaceuticals, Wessex Pharmaceuticals, and Celgene are the major players in the Kenya cancer immunotherapy market.

The Kenya cancer immunotherapy market is expected to grow from $79 Mn in 2022 to $148 Mn in 2030 with a CAGR of 8.2% for the forecasted year 2022-2030.

The Kenya cancer immunotherapy market is segmented by type, application, and end user.


Last updated on: 14 December 2023
Updated by: Bhanu Pratap Singh

Related reports (by category)


Related reports (by geography)


subscribe to our newsletter
up